Table 3.
Approved options for RRMM who received at least 1 prior therapy
| Reference | Treatment | N | ORR (%) | PFS (months) | OS benefit |
|---|---|---|---|---|---|
| TOURMALINE-MM135 | IRd vs Rd |
360 vs 362 |
78.3 vs 72 |
20.6 vs 14.7 |
|
| CASTOR7 | Dara-Vd vs Vd | 243 vs 247 |
82.9 vs 63.2 |
16.7 vs 7.2 |
|
| ENDEAVOR36,37 | Kd vs Vd |
464 vs 465 |
77 vs 63 |
18.7 vs 9.4 |
Yes (Kd) |
| ASPIRE33,34 | KRd vs Rd |
396 vs 396 |
87.1 vs 66.7 |
26.3 vs 17.6 |
Yes (KRd) |
| POLLUX8,41 | Dara-Rd vs Rd | 286 vs 283 |
92.9 vs 76.4 |
44.5 vs 17.5 |
- |
| PANORAMA-138 | Pan-Vd vs Vd |
387 vs 381 |
60.7 vs 54.6 |
11.99 vs 8.08 |
- |
| ELOQUENT-221–26 | Elo-Rd vs Rd |
321 vs 325 |
79 vs 66 |
19.4 vs 14.7 |
- |
| ELOQUENT-327 | Elo-Pd vs Pd |
60 vs 57 |
53 vs 26 |
10.3 vs 4.7 |
- |
| EQUULEUS9 | Dara-Pd | 103 | 60 | 8.8 | - |
Abbreviations: N, number of patients; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; vs, versus; IRd, ixazomib, lenalidomide, dexamethasone; Rd, lenalidomide and dexamethasone; Dara-Vd, daratumumab, bortezomib, dexamethasone; Vd, bortezomib and dexamethasone; Kd, carfilzomib, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; Dara-Rd, daratumumab, lenalidomide, dexamethasone; Rd, lenalidomide and dexamethasone; Pan-Vd, panobinostat, bortezomib, dexamethasone; Elo-Rd, elotuzumab, lenalidomide, dexamethasone; Elo-Pd, elotuzumab, pomalidomide, dexamethasone; Dara-Pd, daratumumab, pomalidomide and dexamethasone.